CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of Lymphokine-Activated Killer (LAK) cells against glioblastoma cell lines T98G and U373MG

Oncology Research

Volumn 12, Issue 1, 2000, Pages 17-24

  Komatsu, Fumio ^a   Kajiwara, Michiko ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Adhesion molecules, Tumor necrosis factor related apoptosis inducing ligand (TRAIL); Lymphokine activated killer cell; NK 92; T98G; U373MG

Indexed keywords

CD18 ANTIGEN; CD2 ANTIGEN; CELL ADHESION MOLECULE; CHROMIUM; GAMMA INTERFERON; ICAM2 PROTEIN, HUMAN; INTERCELLULAR ADHESION MOLECULE 1; LEUKOCYTE ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOSYNTHESIS; CELL ADHESION; CELL CULTURE; CHEMISTRY; CYTOTOXICITY; GLIOBLASTOMA; HUMAN; IMMUNOLOGY; KILLER CELL; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA;

ANTIGENS, CD; ANTIGENS, CD18; ANTIGENS, CD2; ANTIGENS, CD58; CELL ADHESION; CELL ADHESION MOLECULES; CHROMIUM; CYTOTOXICITY, IMMUNOLOGIC; GLIOBLASTOMA; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; KILLER CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LYMPHOMA, NON-HODGKIN; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034567816     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000001108747408     Document Type: Article

References (20)

1. Moretta, A.; Tambussi, G.; Bottino, C.; Tripodi, G.; Merli, A.; Ciccone, E.; Pantaleo, G.; Moretta, L. A novel surface antigen expressed by a subset of human CD3-CD16+ natural killer cells: Role in cell activation and regulation of cytolytic function. J. Exp. Med. 171:695-714; 1990.
2. Vitale, M.; Sivori, S.; Pende, D.; Moretta, L.; Moretta, A. Coexpression of two functionally independent p58 inhibitory receptors in human natural killer cell clones results in the inability to kill all normal allogeneic target cells. Proc. Natl. Acad. Sci. USA 92: 3536-3540; 1995.
3. Gumperz, J. E.; Valiante, N. M.; Parham, P.; Lanier, L. L.; Tyan, D. Heterogenous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigen types appear genetically regulated, but not linked to major histocompatibility complex haplotype. J. Exp. Med. 183:1817-1827; 1996.
4. Dohring, C.; Scheidegger, D.; Samaridis, J.; Cella, M.; Colonna, M. A human killer inhibitory receptor specific for HLA-A. J. Immunol. 156:3098-3101; 1996.
5. Van de Wiel-van Kemenade, E.; Te Velde, A. A.; De Boer, A. J.; Weening, R. S.; Fischer, A.; Borst, J.; Melief, C. J. M.; Figdor, C. G. Both LFA-1-positive and -deficient T cell clones require the CD2/LFA-3 interaction for specific cytolytic activation. Eur. J. Immunol. 22:1467-1475; 1992.
6. Gwin, J. L.; Gercel-Taylor, C.; Taylor, D. D.; Eisenberg, R. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells. J. Surg. Res. 60:129-136; 1996.
7. Osborn, L.; Day, E. S.; Miller, G. T.; Karpusas, M.; Tizard, R.; Meuer, S. C.; Hochman, P. S. Amino acid residues required for binding of lymphocyte function-associated antigen 3 (CD58) to its counter-receptor CD2. J. Exp. Med. 181:429-434; 1995.
8. Gollob, J. A.; Li, J.; Kawasaki, H.; Daley, J. F.; Groves, C.; Reinherz, E. L.; Ritz, J. Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12. J. Immunol. 157:1886-1893; 1996.
9. Gong, J-H.; Maki, G.; Klingeman, H-G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652-658; 1994.
10. Klingemann, H-G.; Wong, E.; Maki, G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transpl. 2:68-75; 1996.
11. Klingemann, H-G.; Miyagawa, B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 87: 4913-4914; 1996.
12. Komatsu, F.; Kajiwara, M. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol. Res. 10:483-489; 1998.
13. Komatsu, F.; Yoshida, S. Characteristics of human T-lymphotropic virus type-1 (HTLV-1)-infected cell line MT-2, which is not killed by a natural killer cell line NK-92 but is killed by lymphokine-activated killer cells. Oncol. Res. 11:213-218; 1999.
14. +-ATPas, on CTL-mediated cytotoxicity. J. Immunol. 153:3938-3947; 1994.
15. Mariani, S. M.; Krammer, P. H. Diffential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 28:973-982; 1998.
16. Jeremias, I.; Herr, I.; Boehler, T.; Debatin, K-M. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol. 28: 143-152; 1998.
17. Montel, A. H.; Bochan, M. R.; Hobbs, J. A.; Lynch, D. H.; Brahmi, Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell. Immunol. 166:236-246; 1995.
18. Arase, H.; Arase, N.; Saito, T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181:1235-1238; 1995.
19. Boldin, M. P.; Goncharov, T. M.; Goltsev, Y. V.; Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85: 803-815; 1996.
20. Chi, S.; Kitanaka, C.; Noguchi, K.; Mochizuki, T.; Nagashima, Y.; Shirouzu, M.; Fujita, H.; Yoshida, M.; Chen, W.; Asai, A.; Himeno, M.; Yokoyama, S.; Kuchino, Y. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene 18:2281-2290; 1999.